Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med    2011, Vol. 5 Issue (1) : 45-52     DOI: 10.1007/s11684-011-0117-y
Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction
Jiong HU()
Department of Hematology, Rui Jin Hospital, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Download: PDF(134 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia. In past decades, intensive studies on the biology and treatment of this disease have resulted in a remarkably thorough understanding of its pathogenesis and improvement of treatment outcomes. In particular, the introduction of all-trans retinoic acid to conventional chemotherapy improved dramatically the remission and survival rates of APL patients and consequently became the major treatment modality for it. In the last decade, the groundbreaking development of arsenic further improved the survival rate of APL patients. As the most active agent in APL, arsenic directly degrades the PML-RARα fusion transcript, leading to the differentiation and apoptosis of leukemia cells and the potential eradication of APL leukemia-initiating cells (LICs), thus making the disease a potentially curable type of leukemia. More notably, the recent development of oral arsenic compounds may further enhance not only clinical outcomes but also the convenience of patients, which may dramatically change the APL clinical scenario in the near future.

Keywords acute promyelocytic leukemia      arsenic      all-trans retinoic acid      survival     
Corresponding Authors: HU Jiong,   
Issue Date: 05 March 2011
URL:     OR
InductionConsolidationMaintenanceCycles of ArsenicRef.
Shanghai Institute of Hematology++621
North American Leukemia Intergroup Study+224
MD Anderson++522-23
Tab.1  Different strategies of arsenic combination with ATRA in the treatment of newly diagnosed APL
1 Rowley J D, Golomb H M, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet , 1977, 1(8010): 549–550
doi: 10.1016/S0140-6736(77)91415-5 pmid:65649
2 Rousselot P, Hardas B, Patel A, Guidez F, G?ken J, Castaigne S, Dejean A, de Thé H, Degos L, Farzaneh F, .The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene , 1994, 9(2): 545–551
3 Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood , 2008, 111(5):2505–2515
4 Huang M E, Ye Y C, Chen S R, Chai J R, Lu J X, Zhoa L, Gu L J, Wang Z Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood , 1988, 72(2): 567–572
5 Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood , 1990, 75(11): 2112–2117
6 Sanz M A, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, Bolufer P, Barragán E, Terol M J, González J D, Colomer D, Chillón C, Rivas C, Gómez T, Ribera J M, Bornstein R, Román J, Calasanz M J, Arias J, Alvarez C, Ramos F, Debén G. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood , 1999, 94(9): 3015–3021
7 Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol , 2009, 27(16): 2668–2676
doi: 10.1200/JCO.2008.18.4119 pmid:19414681
8 Tallman M S, Altman J K. How I treat acute promyelocytic leukemia. Blood , 2009, 114(25): 5126–5135
doi: 10.1182/blood-2009-07-216457 pmid:19797519
9 Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, Zhu J, Tang W, Sun G L, Yang K Q, Chen Y, Zhou L, Fang Z W, Wang Y T, Ma J, Zhang P, Zhang T D, Chen S J, Chen Z, Wang Z Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood , 1997, 89(9): 3354–3360
10 Chen G Q, Zhu J, Shi X G, Ni J H, Zhong H J, Si G Y, Jin X L, Tang W, Li X S, Xong S M, Shen Z X, Sun G L, Ma J, Zhang P, Zhang T D, Gazin C, Naoe T, Chen S J, Wang Z Y, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood , 1996, 88(3): 1052–1061
11 Niu C, Yan H, Yu T, Sun H P, Liu J X, Li X S, Wu W, Zhang F Q, Chen Y, Zhou L, Li J M, Zeng X Y, Yang R R, Yuan M M, Ren M Y, Gu F Y, Cao Q, Gu B W, Su X Y, Chen G Q, Xiong S M, Zhang T D, Waxman S, Wang Z Y, Chen Z, Hu J, Shen Z X, Chen S J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood , 1999, 94(10): 3315–3324
12 Soignet S L, Frankel S R, Douer D, Tallman M S, Kantarjian H, Calleja E, Stone R M, Kalaycio M, Scheinberg D A, Steinherz P, Sievers E L, Coutré S, Dahlberg S, Ellison R, Warrell R P Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol , 2001, 19(18): 3852–3860
13 Mathews V, George B, Lakshmi K M, Viswabandya A, Bajel A, Balasubramanian P, Shaji R V, Srivastava V M, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood , 2006, 107(7): 2627–2632
doi: 10.1182/blood-2005-08-3532 pmid:16352810
14 Mathews V, George B, Chendamarai E, Lakshmi K M, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji R V, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol , 2010, 28(24): 3866–3871
doi: 10.1200/JCO.2010.28.5031 pmid:20644086
15 Ghavamzadeh A, Alimoghaddam K, Ghaffari S H, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol , 2006, 17(1): 131–134
doi: 10.1093/annonc/mdj019 pmid:16227315
16 Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, Li X, Han X, Zhou J, Liu P. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide-an analysis of 242 cases. Chin J Hematol , 2000, 21(2): 67–70
17 Zhou G B, Zhang J, Wang Z Y, Chen S J, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci , 2007, 362(1482): 959–971 17317642
doi: 10.1098/rstb.2007.2026
18 Lallemand-Breitenbach V, Guillemin M C, Janin A, Daniel M T, Degos L, Kogan S C, Bishop J M, de Thé H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med , 1999, 189(7): 1043–1052
doi: 10.1084/jem.189.7.1043 pmid:10190895
19 Jing Y, Wang L, Xia L, Chen G Q, Chen Z, Miller W H, Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood , 2001, 97(1): 264–269
doi: 10.1182/blood.V97.1.264 pmid:11133770
20 Raffoux E, Rousselot P, Poupon J, Daniel M T, Cassinat B, Delarue R, Taksin A L, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand J P, de Thé H, Degos L, Hermine O, Dombret H. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol , 2003, 21(12): 2326–2334
doi: 10.1200/JCO.2003.01.149 pmid:12805334
21 Shen Z X, Shi Z Z, Fang J, Gu B W, Li J M, Zhu Y M, Shi J Y, Zheng P Z, Yan H, Liu Y F, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang Z Y, Chen S J, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA , 2004, 101(15): 5328–5335
doi: 10.1073/pnas.0400053101 pmid:15044693
22 Hu J, Liu Y F, Wu C F, Xu F, Shen Z X, Zhu Y M, Li J M, Tang W, Zhao W L, Wu W, Sun H P, Chen Q S, Chen B, Zhou G B, Zelent A, Waxman S, Wang Z Y, Chen S J, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA , 2009, 106(9): 3342–3347
doi: 10.1073/pnas.0813280106 pmid:19225113
23 Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood , 2006, 107(9): 3469–3473
doi: 10.1182/blood-2005-10-4006 pmid:16373661
24 Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol , 2009, 27(4): 504–510
doi: 10.1200/JCO.2008.18.6130 pmid:19075265
25 Powell B L, Moser B, Stock W, Gallagher R E, Willman C L, Stone R M, Rowe J M, Coutre S, Feusner J H, Gregory J, Couban S, Appelbaum F R, Tallman M S, Larson R A. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood , 2010, 116(19): 3751–3757
doi: 10.1182/blood-2010-02-269621 pmid:20705755
26 Sanz M A, Grimwade D, Tallman M S, Lowenberg B, Fenaux P, Estey E H, Naoe T, Lengfelder E, Büchner T, D?hner H, Burnett A K, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood , 2009, 113(9): 1875–1891
doi: 10.1182/blood-2008-04-150250 pmid:18812465
27 Zhu J, Lallemand-Breitenbach V, de Thé H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene , 2001, 20(49): 7257–7265
doi: 10.1038/sj.onc.1204852 pmid:11704854
28 Zhu J, Zhou J, Peres L, Riaucoux F, Honoré N, Kogan S, de Thé H. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell , 2005, 7(2): 143–153
doi: 10.1016/j.ccr.2005.01.005 pmid:15710327
29 Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honoré N, Doubeikovsky A, Duprez E, Pandolfi P P, Puvion E, Freemont P, de Thé H. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med , 2001, 193(12): 1361–1371
doi: 10.1084/jem.193.12.1361 pmid:11413191
30 Zhang X W, Yan X J, Zhou Z R, Yang F F, Wu Z Y, Sun H B, Liang W X, Song A X, Lallemand-Breitenbach V, Jeanne M, Zhang Q Y, Yang H Y, Huang Q H, Zhou G B, Tong J H, Zhang Y, Wu J H, Hu H Y, de Thé H, Chen S J, Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science , 2010, 328(5975): 240–243
doi: 10.1126/science.1183424 pmid:20378816
31 Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin M C, de Thé H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res , 2009, 15(20): 6321–6326
doi: 10.1158/1078-0432.CCR-09-0209 pmid:19808868
32 Wang J C, Dick J E. Cancer stem cells: lessons from leukemia. Trends Cell Biol , 2005, 15(9): 494–501
doi: 10.1016/j.tcb.2005.07.004 pmid:16084092
33 Grignani F, Ferrucci P F, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, .The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell , 1993, 74(3): 423–431
doi: 10.1016/0092-8674(93)80044-F pmid:8394219
34 Du C, Redner R L, Cooke M P, Lavau C. Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood , 1999, 94(2): 793–802
35 Nasr R, Guillemin M C, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi P P, Rochette-Egly C, Zhu J, de Thé H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med , 2008, 14(12): 1333–1342
doi: 10.1038/nm.1891 pmid:19029980
36 Delva L, Cornic M, Balitrand N, Guidez F, Micléa J M, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, .Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood , 1993, 82(7): 2175–2181
37 Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica , 2007, 92(3): 323–331
doi: 10.3324/haematol.10541 pmid:17339181
38 Kogan S C. Curing APL: differentiation or destruction? Cancer Cell , 2009, 15(1): 7–8
doi: 10.1016/j.ccr.2008.12.012 pmid:19111876
39 Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan D E, Teruya-Feldstein J, Pandolfi P P. PML targeting eradicates quiescent leukaemia-initiating cells. Nature , 2008, 453(7198): 1072–1078
doi: 10.1038/nature07016 pmid:18469801
40 Luesink M, Pennings J L, Wissink W M, Linssen P C, Muus P, Pfundt R, de Witte T J, van der Reijden B A, Jansen J H. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood , 2009, 114(27): 5512–5521
doi: 10.1182/blood-2009-02-204834 pmid:19828696
41 Tallman M S, Andersen J W, Schiffer C A, Appelbaum F R, Feusner J H, Ogden A, Shepherd L, Rowe J M, Fran?ois C, Larson R S, Wiernik P H. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood , 2000, 95(1): 90–95
42 Ng J C, Wang J, Shraim A. A global health problem caused by arsenic from natural sources. Chemosphere , 2003, 52(9): 1353–1359
doi: 10.1016/S0045-6535(03)00470-3 pmid:12867164
43 Ficker E, Kuryshev Y A, Dennis A T, Obejero-Paz C, Wang L, Hawryluk P, Wible B A, Brown A M. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol , 2004, 66(1): 33–44
doi: 10.1124/mol.66.1.33 pmid:15213294
44 Kojima C, Ramirez D C, Tokar E J, Himeno S, Drobná Z, Styblo M, Mason R P, Waalkes M P. Requirement of arsenic biomethylation for oxidative DNA damage. J Natl Cancer Inst , 2009, 101(24): 1670–1681
doi: 10.1093/jnci/djp414 pmid:19933942
45 Hughes M F. Arsenic methylation, oxidative stress and cancer—is there a link? J Natl Cancer Inst , 2009, 101(24): 1660–1661
doi: 10.1093/jnci/djp437 pmid:19933940
46 Lu D P, Qiu J Y, Jiang B, Wang Q, Liu K Y, Liu Y R, Chen S S. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood , 2002, 99(9): 3136–3143
doi: 10.1182/blood.V99.9.3136 pmid:11964275
47 The Cooperation Group of Phase II Clinical Trial of Compound Huangdai Tablet. Phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol , 2006, 27(12): 801–804
48 Sun F, Chen N N, Cheng Y B. Compound realgar and natural indigo tablets in treatment of acute promyelocytic leukemia: a summary of experience in 204 cases. Zhong Xi Yi Jie He Xue Bao , 2008, 6(6): 639–642
doi: 10.3736/jcim20080618 pmid:18559245
49 Au W Y, Kumana C R, Kou M, Mak R, Chan G C, Lam C W, Kwong Y L. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood , 2003, 102(1): 407–408
doi: 10.1182/blood-2003-01-0298 pmid:12814916
50 Siu C W, Au W Y, Yung C, Kumana C R, Lau C P, Kwong Y L, Tse H F. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood , 2006, 108(1): 103–106
doi: 10.1182/blood-2006-01-0054 pmid:16514059
[1] Xinsen Xu,Kai Qu,Qing Pang,Zhixin Wang,Yanyan Zhou,Chang Liu. Association between telomere length and survival in cancer patients: a meta-analysis and review of literature[J]. Front. Med., 2016, 10(2): 191-203.
[2] Lan Wang,Jueheng Wu,Jie Yuan,Xun Zhu,Hongmei Wu,Mengfeng Li. Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo[J]. Front. Med., 2016, 10(1): 41-51.
[3] Yunfeng Fu, Xinyu Wang, Zimin Pan, Xing Xie. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases[J]. Front Med, 2014, 8(1): 91-95.
[4] Renling Pei, Ye Xu, Yan Wei, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie. Association of SIPA1 545 C>T polymorphism with survival in Chinese women with metastatic breast cancer[J]. Front Med, 2013, 7(1): 138-142.
[5] Qinggang Hu, Shanglong Liu, Jianwei Jiang, Chen Zhang, Xiaowei Liu, Qichang Zheng. Potential indicators predict progress after surgical resection of gastrointestinal stromal tumors[J]. Front Med, 2012, 6(3): 317-321.
[6] Kyoung-Woong Kim, Penradee Chanpiwat, Hoang Thi Hanh, Kongkea Phan, Suthipong Sthiannopkao. Arsenic geochemistry of groundwater in Southeast Asia[J]. Front Med, 2011, 5(4): 420-433.
[7] Jianqing Mi. Current treatment strategy of acute promyelocytic leukemia[J]. Front Med, 2011, 5(4): 341-347.
[8] Xi-Yan WANG, Hai-Jun LI, Dong YAN, Hao WEN, Shu-Yong PENG, . Influence of the adjuvant therapy on the survival of patients with stage II pancreatic carcinoma[J]. Front. Med., 2010, 4(4): 430-435.
[9] Zhi-Ruo ZHANG PhD, Jian-Qing MI MD, Zhao-Jun WEN MA, Sai-Juan CHEN MD, PhD, Zhu CHEN PhD, Long-Jun GU MD, Jing-Yan TANG MD, PhD, Shu-Hong SHEN MD, PhD, . Using sound Clinical Paths and Diagnosis-related Groups (DRGs)-based payment reform to bring benefits to patient care: A case study of leukemia therapy[J]. Front. Med., 2010, 4(1): 8-15.
[10] ZHAN Rong, YU Qinghong, HUANG Haobo. Effect of arsenic trioxide on proliferation and apoptosis of U266 cells and its relationship with the expression variation of VEGF[J]. Front. Med., 2008, 2(4): 356-360.
[11] ZOU Yunfeng, NIU Piye, GONG Zhiyong, YANG Jin, YUAN Jing, WU Tangchun, CHEN Xuemin. Relationship between reactive oxygen species and sodium-selenite-induced DNA damage in HepG2 cells[J]. Front. Med., 2007, 1(3): 327-332.
[12] LI Jun, CHENG Xiaotian, WANG Zhenghui, WEN Xinping, HAN Lingling, SANG Zhiping, ZHANG Jie, DUAN Hushun, LIANG Binfeng, GAO Jianguo. Studies on exposure status of inhabitants to water-arsenic valence states in areas with endemic arsenism in the Datong basin in Shanxi[J]. Front. Med., 2007, 1(2): 219-222.
Full text